CDK9 and neoplasm: At submicromolar concentrations, 2 inhibited all tested CDKs in complexes with cognate cyclin partners, whereas 4 preferentially targeted CDK2/cyclin E and CDK9/cyclin K. We were interested in whether the potency in cell-free systems can be translated into the ability to induce the death of human tumor cell lines.